Zenas BioPharma Archives | Page 2 of 2

Home / Posts tagged Zenas BioPharma (Page 2)

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

WALTHAM, Mass., Aug. 1 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, announces The Lancet Rheumatology has published findings from a Phase 2 study evaluating obexelimab for the treatment of patients with IgG4-Related Disease (IgG4-RD). Based on the results of this [...]

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

WALTHAM, Mass., Jan. 11 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of [...]

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

WALTHAM, Mass., Nov. 9 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new [...]

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 7 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 [...]

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass and SHANGHAI, China, July 31 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration [...]

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) [...]

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

BOSTON and SHANGHAI, China, Jan. 6 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of John Orloff, MD to its Board of Directors. Dr. Orloff joins the Zenas Board with over 25 years of experience successfully leading [...]

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21 (Korea Bizwire) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based [...]

Zenas BioPharma Announces New Executive Leadership Appointments

HONG KONG and BOSTON, May 3 (Korea Bizwire) — Zenas BioPharma (“Zenas”), a cross-border (China-USA based) biopharmaceutical company committed to the development and delivery of immune-based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative [...]

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

HONG KONG and BOSTON, March 23 (Korea Bizwire) — Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds [...]